<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553267</url>
  </required_header>
  <id_info>
    <org_study_id>1235.6</org_study_id>
    <secondary_id>EUDRACT 2007-002421-68</secondary_id>
    <nct_id>NCT00553267</nct_id>
  </id_info>
  <brief_title>Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension</brief_title>
  <official_title>An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to demonstrate that the fixed dose combination of
      telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan
      80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks
      compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks
      treatment with A10.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure</measure>
    <time_frame>Baseline and end of study (8 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough DBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure</measure>
    <time_frame>Baseline and end of study (8 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Diastolic Blood Pressure Control (Defined as &lt; 90mmHg)</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Diastolic Blood Pressure &lt;80 mmHg</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;80mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated DBP Response</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Control</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Response</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated BP Normality Classes</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach predefined BP categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oedema Incidence Rate</measure>
    <time_frame>During randomised treatment period</time_frame>
    <description>The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Oedema Incidence Rate</measure>
    <time_frame>During randomised treatment period</time_frame>
    <description>The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)</description>
  </secondary_outcome>
  <enrollment type="Actual">947</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed dose combination of telmisartan+amlodipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of essential hypertension and blood pressure not adequately controlled
             before informed consent (inadequate control defined as seated diastolic blood pressure
             (DBP) &gt;= 95 mmHg if on existing antihypertensive treatment or seated DBP &gt;= 100 mmHg
             if treatment-naïve).

          -  failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond
             defined as seated DBP &gt;= 90 mmHg.)

          -  able to stop any current antihypertensive therapy without unacceptable risk to the
             patient.

          -  willing and able to provide written informed consent.

        Exclusion Criteria:

          -  pregnancy, breast-feeding, unwilling to use effective contraception (if female of
             child-bearing potential).

          -  known or suspected secondary hypertension.

          -  mean seated systolic blood pressure (SBP) &gt;=200 mmHg and/or mean seated DBP &gt;= 120
             mmHg during run-in treatment or mean seated SBP &gt;= 180 mmHg and/or mean seated DBP &gt;=
             120 mmHg at the randomisation visit or at any time during randomised treatment.

          -  any clinically significant hepatic impairment or severe renal impairment bilateral
             renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal
             transplant.

          -  clinically relevant hyperkalaemia.

          -  uncorrected volume or sodium depletion.

          -  primary aldosteronism.

          -  hereditary fructose or lactose intolerance.

          -  symptomatic congestive heart failure.

          -  patients who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or ARBs.

          -  history of drug or alcohol dependency within the six months prior to signing consent.

          -  concurrent participation in another clinical trial or any investigational therapy
             within thirty days prior to signing consent.

          -  hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
             aortic or mitral valve.

          -  known allergic hypersensitivity to any component of the formulations under
             investigation. (Includes known hypersensitivity to telmisartan or other ARBs or
             amlodipine or other dihydropyridine CCBs.)

          -  non-compliance with study medication (defined as less than 80% or more than 120%)
             during the open-label run-in treatment period.

          -  current treatment with any antihypertensive agents, whether or not prescribed for this
             indication, that cannot be safely stopped (investigator¿s decision) by the start of
             the run-in period.

          -  chronic administration of any medication known to affect blood pressure, other than
             the trial medication.

          -  any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of telmisartan and
             amlodipine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.6.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eggenburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hainburg a.d. Donau</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35304 Wilmer Road</name>
      <address>
        <city>Birr</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35305 Dr. Ger McLaughlin</name>
      <address>
        <city>Carrigtwohill</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35302 Slaney Medical Centre</name>
      <address>
        <city>Enniscorthy</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35303 Gorey Medical Centre, Coral House,</name>
      <address>
        <city>Gorey</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35306 The Red House Surgery</name>
      <address>
        <city>Mallow</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Ross</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Broni (pv)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coppito (AQ)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otahuhu, Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.70012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kralovsky Chmlec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34008 Hospital Municipal de Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34001 Hospital Gral de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera (Cádiz)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34006 C.A.P. Mossen Cinto Verdaguer</name>
      <address>
        <city>L'Hospitalet de Llobregat (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34003 Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34004 Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.41005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gordola</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bexhill</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burbage, Hinkley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chestfield, Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ely</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fowey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penzance</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saltash</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Stephen, St Austell</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.6.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <results_first_submitted>November 18, 2009</results_first_submitted>
  <results_first_submitted_qc>November 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2009</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="P2">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
        </group>
        <group group_id="P3">
          <title>Telmisartan 80mg and Amlodipine 10mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="315"/>
                <participants group_id="P3" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="297"/>
                <participants group_id="P3" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Specified category</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="B2">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
        </group>
        <group group_id="B3">
          <title>Telmisartan 80mg and Amlodipine 10mg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="317"/>
            <count group_id="B4" value="947"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="10.4"/>
                    <measurement group_id="B2" value="57.6" spread="9.4"/>
                    <measurement group_id="B3" value="55.5" spread="9.8"/>
                    <measurement group_id="B4" value="56.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough DBP</description>
        <time_frame>Baseline and end of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough DBP</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.48" spread="0.45"/>
                    <measurement group_id="O2" value="-9.24" spread="0.45"/>
                    <measurement group_id="O3" value="-9.33" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing that the combination treatments are superior to monotherapy A10.
The number of patients in the treatment arms ensure the tests have over 90% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Doses tested against A10 in a hierarchical manner to address issues of multiplicity. T80/A10 was tested first, then T40/A10.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>-1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing that the combination treatments are superior to monotherapy A10.
The number of patients in the treatment arms ensure the tests have over 90% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Doses tested against A10 in a hierarchical manner to address issues of multiplicity. T80/A10 was tested first, then T40/A10.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.86</ci_lower_limit>
            <ci_upper_limit>-1.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough SBP</description>
        <time_frame>Baseline and end of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough SBP</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.44" spread="0.66"/>
                    <measurement group_id="O2" value="-11.09" spread="0.66"/>
                    <measurement group_id="O3" value="-11.29" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.15</ci_lower_limit>
            <ci_upper_limit>-2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.35</ci_lower_limit>
            <ci_upper_limit>-2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Diastolic Blood Pressure Control (Defined as &lt; 90mmHg)</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Diastolic Blood Pressure Control (Defined as &lt; 90mmHg)</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Diastolic Blood Pressure &lt;80 mmHg</title>
        <description>The number of patients who reach the target DBP of &lt;80mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Diastolic Blood Pressure &lt;80 mmHg</title>
          <description>The number of patients who reach the target DBP of &lt;80mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (DBP&lt;80 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (DBP&gt;=80 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="267"/>
                    <measurement group_id="O3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>4.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>4.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated DBP Response</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated DBP Response</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Control</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Control</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (SBP&lt;140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (SBP&gt;=140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Response</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Response</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="198"/>
                    <measurement group_id="O3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel−Haenszel statistics adjusted for country effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated BP Normality Classes</title>
        <description>The number of patients who reach predefined BP categories</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated BP Normality Classes</title>
          <description>The number of patients who reach predefined BP categories</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal (SBP&lt;120 and DBP&lt;80 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (SBP&lt;130 and DBP&lt;85 mmHg and not optimal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-normal (SBP&lt;140 DBP&lt;90 mmHg and not normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1 hypertension (SBP&lt;160 and DBP&lt;100 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2 hypertension (SBP&gt;=160 and DBP&gt;=100 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon rank sum test</method>
            <method_desc>Stratified (for country) Wilcoxon rank sum test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank sum test</method>
            <method_desc>Stratified (for country) Wilcoxon rank sum test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oedema Incidence Rate</title>
        <description>The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)</description>
        <time_frame>During randomised treatment period</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Oedema Incidence Rate</title>
          <description>The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward</population>
          <units>Number of patients/100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="42.8"/>
                    <measurement group_id="O3" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Oedema Incidence Rate</title>
        <description>The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)</description>
        <time_frame>During randomised treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Oedema Incidence Rate</title>
          <description>The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)</description>
          <units>Number of cases/100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="E2">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
        </group>
        <group group_id="E3">
          <title>Telmisartan 80mg and Amlodipine 10mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="3"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22"/>
                <counts group_id="E2" subjects_affected="21"/>
                <counts group_id="E3" subjects_affected="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral oedema</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

